Answers are grounded in this paper and cite their sources.
At APCCC 2022, clinically important questions in the management of advanced prostate cancer management were identified and discussed, and experts voted on pre-defined consensus questions. The report of the results for metastatic and/or castration-resistant prostate cancer is summarised here.
No takes yet. Share an insight, caveat, or question.
Gillessen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: